Friday, July 10, 2026

pharma · Obesity, Overweight · Type 2 Diabetes

Eli Lilly and

Eli Lilly Co is a pharma organization headquartered in EU. Primary therapeutic focus areas include Obesity, Overweight, Type 2 Diabetes, Ulcerative Colitis, Type 2 Diabetes Mellitus, Breast Cancer. NovaPharmaNews links 1

Lilly Corporate Center, Indianapolis, Indiana 46285, US HQ
1876 Founded
55,860 Employees
EMA registrant Type
Company details
Status
Public
HQ
Lilly Corporate Center, Indianapolis, Indiana 46285, US
Founded
1876
Employees
55,860
Programs
107
Drugs
99
Patents
0
Clinical program

LOXO-IDH-20001

Phase 1 · other · Advanced Hematologic Malignancies

LOXO-IDH-20001 for Advanced Hematologic Malignancies is a Phase 1 program (other) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).

Internal code LOXO-IDH-20001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Eli Lilly Co.
Phase
Phase 1
Modality
other
Indication
Advanced Hematologic Malignancies
Status
active
Trials
1